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RESUMO – Angioedema caracteriza-se por edema transitório e localizado da derme e submucosa secundário à libertação de 
mediadores vasoativos de origem mastocitária ou não. Podem também ser formas agudas ou crónicas, hereditárias ou aquiri-
das. Os aspectos clínicos, em particular nos sintomas associados, e os mecanismos fisiopatológicos subjacentes a cada tipo de 
angioedema são distintos, devendo os dermatologistas estar capacitados para o seu reconhecimento uma vez que cada um im-
plica diferentes abordagens diagnósticas e terapêuticas, e distintos prognósticos. Este artigo revê a classificação, o diagnóstico 
e o tratamento dos diferentes tipos de angioedema. 
PALAVRAS-CHAVE – Angioedema/classificação; Angioedema/diagnóstico; Angioedema/genética; Angioedema/tratamento.
The Different Faces of Angioedema: Classification, 
Diagnosis and Management
ABSTRACT – Angioedema is a transient localized and self-limiting edema of the subcutaneous and submucosal tissue, due to the 
release of vasoactive mediators. However, different mechanisms are at the origin of the different types of angioedema (acute or 
chronic, related or not with mast cell mediators and genetic and familial or acquired). Dermatologists should be able to recognize 
the different forms of angioedema as associated symptoms, treatment and prognostic factors are completely different. This paper 
reviews the classification of angioedema, diagnostic tests and management. 
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INTRODUCTION
Angioedema is a frequent clinical condition that someti-
mes can be life-threatening.  Different mechanisms and va-
soactive mediators are implicated in the different forms of 
angioedema. As each type of angioedema requires distinct 
treatment approaches and prompt diagnosis is the most im-
portant prognostic factor, dermatologists should be aware of 
the classification of angioedema (acute or chronic, hereditary 
or acquired) and appropriate management of each. This re-
view focuses on classification, diagnostic tests and treatment 
of angioedema.
1. DEFINITION
Angioedema is a transient (48-72 hours) localized and 
self-limiting edema of the subcutaneous and submucosal 
tissue, due to the release of vasoactive mediators and a 
temporary increase in vascular permeability.1 It frequently 
affects the face, with swollen eyelids and lips, usually with 
an asymmetric distribution, which can be disfiguring and di-
sabling. The swollen areas are larger and less well-defined 
than wheals and tend to be faint pink or normal in color. 
There may be pain or pruritus. Angioedema frequently oc-
curs in association with urticaria (wheals) but isolated an-
gioedema (without wheals) is not uncommon,2 accounting 
for about 10% of cases of recurrent lesions.3 When associa-
ted with wheals and in most cases of isolated angioedema, 
this is a mast-cell driven condition. Some cases of isola-
ted recurrent angioedema, which are bradykinin-mediated, 
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have a distinct prognosis and need special therapy. Most are 
hereditary, but acquired cases can also occur.
2. CLINICAL RELEVANCE
Angioedema is a relatively common presentation in the 
emergency department (ED), accounting for about one mi-
llion ED visits each year in the United States,4 with heredi-
tary angioedema (HAE) responsible for 2280 to 5000 visits. 
This data may underestimate the true level of angioedema-
-related ED use.5,6 A survey in UK revealed that only 30% 
of patients with hereditary or acquired angioedema have 
visited the ED.7 This may be a life-threatening situation that 
requires immediate intervention but most cases, particularly 
chronic and relapsing cases associated with urticaria, do not 
carry that risk and doctors need to distinguish the different 
forms in order to avoid excessive intervention at the emer-
gency and inform the patient on the absence of significant 
risk in these cases. 
3. CLASSIFICATION AND PATHOPHYSIOLOGY 
Angioedema can occur as an isolated acute episode or 
as chronic and relapsing form. Moreover there are several 
types of acquired angioedema (AAE) and several hereditary 
angioedema (HAE), with distinct underlying pathophysiology 
(Fig.1).
Acute acquired angioedema can occur in the context of 
acute urticaria or anaphylaxis. Chronic recurrent angioede-
ma occurs mostly in association with chronic spontaneous ur-
ticaria, or rarely, chronic inducible urticaria and even in the 
setting it can occur without evident wheals in about 10% of 
the cases. Chronic and relapsing angioedema without urti-
caria can also be a manifestation of the different forms of 
hereditary angioedema or of the rare acquired forms of an-
gioedema.   
Angioedema is mostly due to mast cell activation and de-
granulation, dependent or not on IgE, and results from the 
effect of histamine and other vasoactive mediators (cysteinyl 
leukotrienes, prostaglandins, or platelet-activating factor) on 
blood vessels.1 Basophils also participate, particularly in ana-
phylaxis, which presents with laryngeal edema, bronchos-
pasm with respiratory distress, hypotension, and bradycardia, 
an acute and potentially fatal condition.8 In acute forms, the 
main causes are medications, food, and insect bites/stings 
to which the individuals are sensitized and have specific IgE. 
Angioedema may also be mediated by bradykinin. This 
occurs due to the activation of the kallikrein system either by 
kininogen, activated factor XII (Hageman factor) or the classic 
complement pathway (C2a-kinin like), particularly in indivi-
duals who lack inhibiting factors (C1-INH deficiency), as in 
the hereditary forms of angioedema. Lymphoproliferative or 
autoimmune diseases may also lead to inactivation of C1-
-INH, causing an acquired form of angioedema. Drugs like 
angiotensin-converting enzyme (ACE) inhibitors that reduce 
the breakdown of bradykinin may be responsible for acqui-
red angioedema related to angiotensin-converting enzyme 
(ACEI-AAE).9,10 
4. CLINICAL PRESENTATION, DIAGNOSTIC TESTS, 
AND MANAGEMENT (FIG.4)
4.1 Acute angioedema 
An acute attack of angioedema may have an allergic 
(specific IgE) or pseudoallergic cause and may be a pre-
senting feature of anaphylaxis. It develops very quickly after 
exposure to the culprit medication, food, or venom, may 
coexist with wheals and is soon followed by other symptoms 
and signs of anaphylaxis. This form of acute angioedema 
responds to high dose steroids or epinephrine. Serum tryp-
tase may be high is this setting and becomes normal after 
resolution of the acute attack. Later it may be indicated to 
perform an appropriate allergy work-up (specific IgE, skin 
prick tests, and provocation tests).  
4.2. Chronic/recurrent mast-cell dependent an-
gioedema
Chronic or recurrent mast-cell dependent angioedema 
(MCD-AAE), also called histaminergic acquired angioe-
dema, is the most common form of angioedema without 
wheals, but most often it is associated with wheals in chronic 
spontaneous urticaria. It can be autoallergic (IgE-mediated 
autoimmunity type I), autoimmune (autoimmunity type II 
with IgG antibodies recognizing the high affinity IgE recep-
tor (FcεRI) or IgE) or from an unknown cause, as shown for 
chronic spontaneous urticaria.11 Physical stimuli can also in-
duce angioedema (vibratory angioedema),12 as in chronic 
inducible urticaria.
There is no specific age for the onset of MCD-AAE and as 
in CSU females are more often affected. In this setting swe-
lling develops rapidly, reaching a maximum within 6 hours, 
fades in 24-48 hours, and recurs at a variable frequency. 
The face is mostly affected (Fig. 2), but gastrointestinal and 
laryngeal mucosae are spared, therefore with no potential 
risk of asphyxia.12 This type of angioedema responds to oral 
steroids and epinephrine in the acute stage. H1 anti-his-
tamines used prophylactically on a daily basis, often in up 
to fourfold the recommended dose, are also considered as 
the first line in the treatment and prevention of attacks. Ne-
vertheless, the presence of angioedema in association with 
chronic spontaneous urticaria often predicts a non-response 
to H1 anti-histamines,13 and second or third line therapy, 
respectively omalizumab or cyclosporine, may be necessary. 
Chronic/recurrent MCD-AAE is diagnosed by clinical 
features (association with urticaria), exclusions findings (ab-
sence of abdominal and laryngeal attacks, no family history, 
normal laboratory tests, although D-dimers and C-RP may 
be slightly elevated during the attacks) and by therapeutic 
response to H1 anti-histamines, steroids, and, eventually, 
epinephrine. 
4.3. Acquired angioedema related to angioten-
sin-converting enzyme inhibitors (ACEI-AAE)
During treatment of hypertension with captopril or re-
lated ACEI drugs, the inhibition of the angiotensin conver-
ting enzyme involved in the breakdown of bradykinin results 
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in elevated plasma levels of bradykinin that further increa-
se during angioedema.8,9 Angioedema occurs in <0.5% 
of treated patients, 3–4.5-fold more often in black than in 
Caucasian subjects, more in women, and in patients older 
than 65 years.14-19 The latency period between the initia-
tion of ACEI therapy and the onset of symptoms varies from 
a few hours to several years, but it is more likely to occur 
shortly after initiation of therapy.16,20-23 This type of angioe-
dema usually involves the face, lips, eyelids, tongue, neck, 
and upper airways24 (Fig. 3). Death may occur from laryn-
geal edema due to ACEI-AAE.24-26
There are no specific tests for this type of angioedema. 
The diagnosis is based upon the existence of angioedema 
with no wheals, absence of family history, exposure to ACEI 
Revista SPDV 77(2) 2019; The different faces of angioedema; Mariana Batista, F. Alves, Margarida Gonçalo.
Figure 1 - Schematic classification of chronic / recurrent angioedema without wheals. 
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and response to icatibant. This agent, which inhibits bra-
dykinin β2receptors and is licensed to treat C1-INH defi-
ciency hereditary angioedema, has been shown to reverse 
symptoms in ACEI-AAE.27 
The culprit drug should be immediately discontinued and 
a switch to a different antihypertensive therapy is indicated, 
preferably not a sartan derivative, as it may also interfere 
with bradykinin degradation.28 Even after ACEI withdrawal, 
some patients may have recurrent angioedema.29 Such pa-
tients	could	be	slow	bradykinin	"catabolizers",	have	"hidden"	
InH-AAE disclosed by ACEI, or are exposed to other drugs 
involved in bradykinin metabolism.30
Other drugs have recently been suggested as possibly 
involved in attacks of angioedema without wheals, namely 
the gliptins used for diabetes mellitus as they inhibit dipep-
tidyl peptidase 4 also involved in bradykinin metabolism.1
4.4. Acquired angioedema with C1 inhibitor de-
ficiency 
Acquired angioedema with C1 inhibitor deficiency with 
no mutations in C1-INH gene (SERPING1) and no family his-
tory of angioedema, can occur in patients with lymphoproli-
ferative or autoimmune diseases,32-35 due to C1 and C1-INH 
consumption.32,36-8 The prevalence in the general population 
is estimated to approximate 1 : 500 000.39 
This form of AAE begins after the age of 40% in 94% 
of patients, predominantly involves the face, tongue, uvula, 
and upper airways, and can affect any location. Gastroin-
testinal attacks are less common than in HAE.40,41
As in HAE, plasma levels of C1-INH protein are redu-
ced, its functional activity is below 50%, and a significant re-
duction in C4 is almost invariably present. Genetic analysis 
may be necessary to exclude a SERPING1 mutation. Routine 
clinical testing should be performed to rule out a lympho-
proliferative or autoimmune disease or a monoclonal gam-
mopathy of undetermined significance.42 
Treatment of the underlying lymphoproliferative disease 
resolves angioedema attacks. With slow-growing lymphopro-
liferative diseases that do not require treatment per se, mana-
gement of angioedema attacks may have to be considered.
C1-INH replacement therapy is associated with a good 
response in most patients,43 but with acute life-threatening 
attacks, doses of C1-INH concentrate higher than in HAE 
may be needed. On demand subcutaneous icatibant, or the 
subcutaneous plasma kallikrein inhibitor ecallantide, have 
been reported to be efficacious.44,45 Prophylactic therapy can 
be performed with C1-INH or tranexamic acid.43,46
4.5. Hereditary angioedema (HAE)
Hereditary angioedema often occurs due to C1-inhibi-
tor deficiency (C1-INH-HAE). This is a relatively rare auto-
somal-dominant disorder with an estimated prevalence of 
1:10 000 - 1:100 000 inhabitants.47,48 Mutations in one of 
the two alleles of C1-INH gene, SERPING1, result in reduced 
plasma levels of C1-INH and instability of the contact system 
with facilitated release of bradykinin. There are two main 
phenotypic variants: 
•	 type	I	with	a	quantitative	decrease	in	C1-INH	and	con-
sequently diminished functional activity (C1-INH-HAE 
type I) 
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Figure 2 - Lip angioedema in a patient with chronic spontaneous 
urticaria.   
Figure 3 - Assymmetrical facial angioedema with significant disfigure-
ment in a patient taking lisinopril.    
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•	 type	 II	with	normal	or	high	 levels	of	C1-INH	protein,	
which is dysfunctional (C1-INH-HAE type II).49 
In HAE cases with normal C1-INH activity, previously cal-
led	"hereditary	angioedema	type	III",	approximately	20%	of	
affected individuals have a heterozygous gain-of-function 
mutation in the gene that encodes FXII, which activates the 
kallikrein system and secondarily kininogen to produce bra-
dykinin. The term, factor XII-HAE (FXII-HAE), has been pro-
posed for these patients.1 There are still other cases of HAE 
with normal C1-INH with no known cause. 
HAE presents with recurrent, localized subcutaneous or 
submucosal edema lasting for 2–5 days, involving the skin, 
upper airways, gastrointestinal tract, and renal system. The 
clinical expression is highly variable, ranging from asympto-
matic presentations to life-threatening attacks, mostly rela-
ted to asphyxia.50,51 Skin swelling affect mainly the face and 
the extremities. Urticaria does not occur at any time in these 
patients, but transient “erythema marginatum” preceding 
the attacks sometimes occurs with C1-INH-HAE. Almost all 
patients have recurrent attacks of crampy abdominal pain 
and vomiting, caused by transient bowel obstruction due to 
mucosal edema.48,52 This is often misdiagnosed as a surgical 
emergency and treated with unnecessary surgery. 
Swellings in C1-INH-HAE, both type I or II, begin early in 
life, at puberty, or in early adulthood. In FXII-HAE and HAE 
of unknown cause, the age of onset is later, usually in the 
second decade.53 Both sexes are equally affected except in 
FXII-HAE, which affects almost only women. F12 gene mu-
tations are transmitted as an autosomal dominant trait with 
low penetrance: asymptomatic carriers are >90% in men 
and around 40% in women.54-56 In many women, the clinical 
findings are induced or aggravated by oral contraceptives, 
hormonal replacement therapy, or pregnancy.
Patients with C1-INH-HAE have a low C4, even in be-
tween attacks.58 C2 is also frequently low, as it is consumed 
due to the activation of the classic complement pathway la-
cking its physiologic inhibitor C1-INH. Low plasma C1-INH 
levels (50% below the normal value) confirm the diagnosis,58 
but in 15% of the patients, only C1-INH functional activity is 
low (type II).  The diagnosis should be based on two serum 
determination with reduced C4 and low quantitative and/
or functional C1-INH, separated by 1–3 months.59 Genetic 
testing is needed during the first years, as C1-INH plasma 
levels may be falsely low. 
Diagnosis of HAE of unknown cause is purely based on 
clinical findings and requires:
•	 the	above-mentioned	clinical	symptoms
•	 one	or	more	affected	family	members
•	 exclusion	 of	 familial	 and	 hereditary	 chronic	 urticaria	
with associated angioedema
•	 normal	 C1-INH	 activity	 and	 protein	 in	 plasma,	 no	
HAE-associated mutation in F12 gene. FXII-HAE has 
analogous clinical criteria with a F12 gene mutation.60 
It must be remembered that in an emergency, when 
blood tests are not yet available, a family history of similar 
presentations and the association of abdominal symptoms 
with bowel edema and peritoneal effusion observed by ul-
trasonography can confirm an abdominal attack of HAE, 
thus avoiding unnecessary surgery.
Treatment of the acute attacks in C1-INH-HAE is based 
on replacement therapy with intravenous C1-INH concen-
trate or recombinant C1-INH, bradykinin inhibition with the 
subcutaneous specific bradykinin β2 receptor antagonist 
icatibant, or kallikrein inhibition with subcutaneous ecallan-
tide. Prompt therapy at the emergency room or at home 
has shown to be life-saving.61 Fresh frozen plasma may be 
given as an alternative to C1-INH concentrate if the latter 
is unavailable. There is no consensual treatment for other 
forms of HAE but C1-INH replacement, icatibant, ecallanti-
de, progesterone, danazol, and tranexamic acid have been 
proposed.
In patients with frequent or severe attacks, continuous 
treatment should be considered, either recombinant C1 
esterase inhibitor (Cinryze®) or with lanadelumab, a new 
human monoclonal antibody that targets plasma kallikrein 
and has recently been approved by the FDA.62 Attenuated 
androgens (danazol, stanazolol) that increase hepatic syn-
thesis of C1-INH or antifibrinolytic agents (oral tranexamic 
acid) can also reduce frequency and severity of attacks. Side 
effects of long-term treatment include virilizing effects, he-
patic inflammation and adenomas for danazol,64 and in-
creased risk of thrombosis for tranexamic acid.64 
Prophylactic treatment should always be reinforced in 
C1-INH-HAE patients prior to medical maneuvers, name-
ly dental procedures or general anesthesia that can cause 
local trauma and may trigger upper airways edema.65 Plas-
ma-derived or recombinant C1-INH, given as close as pos-
sible to the procedure, is the most rational approach.60 Oral 
tranexamic acid (1 g four times daily in adults or 500 mg 
four times daily in children) for 48 hours before and after 
the procedure, or an increase in established maintenance 
doses of tranexamic acid or danazol can also be effective 
as prophylaxis.
As HAE may be induced or exacerbated by estrogens, 
oral contraceptive pills or hormone replacement therapy 
should be avoided, if possible.
CONCLUSION
Different types of angioedema can be challenging to 
distinguish clinically. However, establishing a correct diag-
nosis is critical as different forms of angioedema require 
distinct treatment approaches. Thus, for example, icatibant 
or C1-INH replacement therapy is indicated in HAE whe-
reas these drugs have no effect on angioedema associated 
with chronic spontaneous urticaria. Likewise, epinephrine 
administration will have no effect on an acute attack of HAE 
in contrast to angioedema in the context of anaphylaxis.  A 
detailed anamnesis, careful physical examination and sear-
ch for additional clinical signs are the key to the correct 
diagnosis (Fig. 4). On the other hand, only after an ac-
curate diagnosis, appropriate management strategies are 
possible.
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1.  Concerning acquired angioedema, which of 
the following is incorrect:
a) In chronic/recurrent mast-cell dependent angioe-
dema there are potential risk of asphyxia. 
(b) H1 anti-histamines are used as first-line therapy 
in chronic/recurrent mast-cell dependent angioe-
dema.
(c) In angioedema related to angiotensin-converting 
enzyme inhibitors (ACEI) the latency period be-
tween the initiation of ACEI therapy and the onset 
of symptoms varies from a few hours to several 
years.
(d) Acquired angioedema with C1 inhibitor deficiency 
can occur in patients with lymphoproliferative or 
autoimmune diseases.
(e) Epinephrine can be used for the treatment of an-
gioedema in the context of anaphylaxis.
2. In chronic/recurrent mast-cell dependent an-
gioedema gastrointestinal and laryngeal 
mucosae are spared, so there is no risk o of 
asphyxia.
 Which of the following is false regarding here-
ditary angioedema (HAE):
a) There are two main phenotypic variants: type I 
and type II.
(b) Typically subcutaneous or submucosal edema lasts 
for 2–5 days.
(c) May be induced or exacerbated by estrogens.
(d) Epinephrine is a first-line therapy in an emergency 
setting of HAE.
(e) Icatibant is a possible therapeutic option.
VErifiquE o quE aprENdEu
Correct answers: 1a) e 2d) Epinephrine does not have effect on an acute attack of HAE.
